Search research articles
Contact Us
Filters
Showing results (71-80 of 121) with videos related to
Page
of 13
Sort By:
Bioorganic & Medicinal Chemistry
|
June 29, 2010
Hypoxic selectivity and solubility--investigating the properties of A-ring substituted nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-ones (nitroCBIs) as hypoxia-activated prodrugs for antitumor therapy
Moana Tercel, Shangjin Yang, Graham J Atwell, et al.
Biochemical Pharmacology
|
August 19, 2014
Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5
Jingli Wang, Chris P Guise, Gabi U Dachs, et al.
International Journal of Radiation Biology
|
September 7, 2019
Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia
Tet Woo Lee, Way Wua Wong, Benjamin D Dickson, et al.
Journal of Medicinal Chemistry
|
May 16, 2003
Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores
Moana Tercel, Stephen M Stribbling, Hilary Sheppard, et al.
Cancer Research
|
April 16, 2009
DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity
Rachelle S Singleton, Christopher P Guise, Dianne M Ferry, et al.
Bioorganic & Medicinal Chemistry
|
March 22, 2014
Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisers
Muriel Bonnet, Cho Rong Hong, Yongchuan Gu, et al.
Bioorganic & Medicinal Chemistry
|
July 22, 2011
N-alkylated cyclen cobalt(III) complexes of 1-(chloromethyl)-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinolin-5-ol DNA alkylating agent as hypoxia-activated prodrugs
Guo-Liang Lu, Ralph J Stevenson, John Yu-Chih Chang, et al.
Biochemical Pharmacology
|
August 23, 2018
Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects
Cho Rong Hong, Benjamin D Dickson, Jagdish K Jaiswal, et al.
Cancer Biology & Therapy
|
April 15, 2015
Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma
Maria R Abbattista, Stephen M F Jamieson, Yongchuan Gu, et al.
Molecular Pharmacology
|
October 11, 2011
Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia
Christopher P Guise, Maria R Abbattista, Smitha R Tipparaju, et al.
Page
of 13
Search research articles
Search
Showing results (71-80 of 121) with videos related to
Sort By:
Page
of 13
Bioorganic & Medicinal Chemistry
|
June 29, 2010
Hypoxic selectivity and solubility--investigating the properties of A-ring substituted nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-ones (nitroCBIs) as hypoxia-activated prodrugs for antitumor therapy
Moana Tercel, Shangjin Yang, Graham J Atwell, et al.
Biochemical Pharmacology
|
August 19, 2014
Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5
Jingli Wang, Chris P Guise, Gabi U Dachs, et al.
International Journal of Radiation Biology
|
September 7, 2019
Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia
Tet Woo Lee, Way Wua Wong, Benjamin D Dickson, et al.
Journal of Medicinal Chemistry
|
May 16, 2003
Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores
Moana Tercel, Stephen M Stribbling, Hilary Sheppard, et al.
Cancer Research
|
April 16, 2009
DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity
Rachelle S Singleton, Christopher P Guise, Dianne M Ferry, et al.
Bioorganic & Medicinal Chemistry
|
March 22, 2014
Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisers
Muriel Bonnet, Cho Rong Hong, Yongchuan Gu, et al.
Bioorganic & Medicinal Chemistry
|
July 22, 2011
N-alkylated cyclen cobalt(III) complexes of 1-(chloromethyl)-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinolin-5-ol DNA alkylating agent as hypoxia-activated prodrugs
Guo-Liang Lu, Ralph J Stevenson, John Yu-Chih Chang, et al.
Biochemical Pharmacology
|
August 23, 2018
Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects
Cho Rong Hong, Benjamin D Dickson, Jagdish K Jaiswal, et al.
Cancer Biology & Therapy
|
April 15, 2015
Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma
Maria R Abbattista, Stephen M F Jamieson, Yongchuan Gu, et al.
Molecular Pharmacology
|
October 11, 2011
Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia
Christopher P Guise, Maria R Abbattista, Smitha R Tipparaju, et al.
Page
of 13